Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion
This has created a demand for more sustainable, less invasive solutions that target the cause rather than the effect
Zhang J, Gold KA, Lin HY, Swisher SG , Lippman SM, Lee JJ, Kim ES, William WN
At both Weeks 26 and 52, the proportion of subjects in clinical remission and clinical response was numerically higher in the high dose group compared to the low dose group (Table 14)
Novo commanded over 70% market share at its peak, with healthcare systems worldwide adopting semaglutide-based treatment protocols
A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate